Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer
Abstract Objective To investigate the predictive value of body composition parameters for biochemical response to abiraterone acetate (AA) in metastatic castration‐resistant prostate cancer (mCRPC) patients with prior chemohormonal therapy. Methods We retrospectively evaluated the clinicopathologic...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5640 |
| _version_ | 1797838360055644160 |
|---|---|
| author | Zhi‐Bin Ke Qi You Yu‐Ting Xue Jiang‐Bo Sun Jia‐Yin Chen Wen‐Qi Liu Yong Wei Qing‐Shui Zheng Xiao‐Dong Li Xue‐Yi Xue Ning Xu |
| author_facet | Zhi‐Bin Ke Qi You Yu‐Ting Xue Jiang‐Bo Sun Jia‐Yin Chen Wen‐Qi Liu Yong Wei Qing‐Shui Zheng Xiao‐Dong Li Xue‐Yi Xue Ning Xu |
| author_sort | Zhi‐Bin Ke |
| collection | DOAJ |
| description | Abstract Objective To investigate the predictive value of body composition parameters for biochemical response to abiraterone acetate (AA) in metastatic castration‐resistant prostate cancer (mCRPC) patients with prior chemohormonal therapy. Methods We retrospectively evaluated the clinicopathologic information of 132 mCRPC cases receiving AA treatment after chemohormonal therapy at hormone‐sensitive stage from July 2018 to June 2021. All patients were divided into AA responders and non‐responders according to the biochemical response to AA (prostate‐specific antigen (PSA) reduction ≥50% than pretreatment). Multivariate Logistic analysis was used to determine the independent predictors and develop predictive model of biochemical response to AA. Cox regression analysis was utilized to investigate the prognostic factors for time to biochemical progression (TTBP), radiological progression‐free survival (rPFS), failure‐free survival (FFS), and overall survival (OS) after AA treatment. Results There were 57 AA responders and 75 AA non‐responders. Periprostatic fat area/prostate area (PPFA/PA) was decreased and skeletal muscle index (SMI) was increased in AA responders compared with AA non‐responders. Multivariable logistic analysis demonstrated that ADT duration ≥12 months, bone metastasis only, high SMI and low PPFA/PA were independent predictors of biochemical response to AA treatment. The FFS, TTBP, rPFS, and OS of patients with lower SMI or higher PPFA/PA was decreased compared with that of patients with higher SMI or lower PPFA/PA, respectively. Combining SMI, PPFA/PA, ADT duration and metastatic sites performed well in differentiating AA responders from non‐responders. Conclusions High SMI and low PPFA/PA could predict biochemical response to AA treatment and preferable prognosis in mCRPC patients with prior chemohormonal therapy at hormone‐sensitive stage. |
| first_indexed | 2024-04-09T15:40:37Z |
| format | Article |
| id | doaj.art-2b14f71ee8444497a420278c3ad6cbe8 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T15:40:37Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-2b14f71ee8444497a420278c3ad6cbe82023-04-27T10:12:43ZengWileyCancer Medicine2045-76342023-04-011278251826610.1002/cam4.5640Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancerZhi‐Bin Ke0Qi You1Yu‐Ting Xue2Jiang‐Bo Sun3Jia‐Yin Chen4Wen‐Qi Liu5Yong Wei6Qing‐Shui Zheng7Xiao‐Dong Li8Xue‐Yi Xue9Ning Xu10Department of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaDepartment of Urology, Urology Research Institute, the First Affiliated Hospital Fujian Medical University Fuzhou ChinaAbstract Objective To investigate the predictive value of body composition parameters for biochemical response to abiraterone acetate (AA) in metastatic castration‐resistant prostate cancer (mCRPC) patients with prior chemohormonal therapy. Methods We retrospectively evaluated the clinicopathologic information of 132 mCRPC cases receiving AA treatment after chemohormonal therapy at hormone‐sensitive stage from July 2018 to June 2021. All patients were divided into AA responders and non‐responders according to the biochemical response to AA (prostate‐specific antigen (PSA) reduction ≥50% than pretreatment). Multivariate Logistic analysis was used to determine the independent predictors and develop predictive model of biochemical response to AA. Cox regression analysis was utilized to investigate the prognostic factors for time to biochemical progression (TTBP), radiological progression‐free survival (rPFS), failure‐free survival (FFS), and overall survival (OS) after AA treatment. Results There were 57 AA responders and 75 AA non‐responders. Periprostatic fat area/prostate area (PPFA/PA) was decreased and skeletal muscle index (SMI) was increased in AA responders compared with AA non‐responders. Multivariable logistic analysis demonstrated that ADT duration ≥12 months, bone metastasis only, high SMI and low PPFA/PA were independent predictors of biochemical response to AA treatment. The FFS, TTBP, rPFS, and OS of patients with lower SMI or higher PPFA/PA was decreased compared with that of patients with higher SMI or lower PPFA/PA, respectively. Combining SMI, PPFA/PA, ADT duration and metastatic sites performed well in differentiating AA responders from non‐responders. Conclusions High SMI and low PPFA/PA could predict biochemical response to AA treatment and preferable prognosis in mCRPC patients with prior chemohormonal therapy at hormone‐sensitive stage.https://doi.org/10.1002/cam4.5640abiraterone acetatebody composition parametersmetastatic castration‐resistant prostate cancerprognosistherapeutic response |
| spellingShingle | Zhi‐Bin Ke Qi You Yu‐Ting Xue Jiang‐Bo Sun Jia‐Yin Chen Wen‐Qi Liu Yong Wei Qing‐Shui Zheng Xiao‐Dong Li Xue‐Yi Xue Ning Xu Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer Cancer Medicine abiraterone acetate body composition parameters metastatic castration‐resistant prostate cancer prognosis therapeutic response |
| title | Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer |
| title_full | Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer |
| title_fullStr | Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer |
| title_full_unstemmed | Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer |
| title_short | Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration‐resistant prostate cancer |
| title_sort | body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration resistant prostate cancer |
| topic | abiraterone acetate body composition parameters metastatic castration‐resistant prostate cancer prognosis therapeutic response |
| url | https://doi.org/10.1002/cam4.5640 |
| work_keys_str_mv | AT zhibinke bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT qiyou bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT yutingxue bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT jiangbosun bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT jiayinchen bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT wenqiliu bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT yongwei bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT qingshuizheng bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT xiaodongli bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT xueyixue bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer AT ningxu bodycompositionparameterswereassociatedwithresponsetoabirateroneacetateandprognosisinpatientswithmetastaticcastrationresistantprostatecancer |